#United States #Draper #Chief Financial Officer #CenExel #Bethany Sensenig

CenExel Appoints Bethany Sensenig as Chief Financial Officer

CenExel, a prominent clinical research site network in the United States, has recently bolstered its leadership team with the appointment of Bethany Sensenig as the new Chief Financial Officer (CFO). This strategic decision comes as part of CenExel's efforts to expand its capabilities within the rapidly evolving clinical research landscape.

Bethany Sensenig brings nearly three decades of experience in the biopharmaceutical sector, having held pivotal roles focused on finance, corporate strategy, and overall operations. Her past achievements include senior positions in both commercial and clinical-stage organizations, where she was instrumental in promoting growth and optimizing financial performance.

Prior to joining CenExel, Sensenig served as the CFO and Head of Operations at Radius Health, a role in which she played a crucial part in growing the private equity-backed company, significantly enhancing its commercial and financial success. Her track record of successful leadership within the biopharmaceutical industry positions her as a vital asset to CenExel.

Sy Pretorius, the CEO of CenExel, emphasized the importance of Sensenig’s appointment, highlighting that it represents the organization's commitment to investing in its leadership team. “As the clinical research landscape continues to evolve, Bethany will play a crucial role in ensuring CenExel remains at the forefront of innovation, quality, and growth,” said Pretorius.

Sensenig’s hiring follows a series of leadership enhancements made by CenExel in 2026, notably including the appointment of Sy Pretorius as CEO in May. These strategic appointments are geared towards positioning CenExel as the largest and most capable site network in the U.S., particularly in clinical research.

CenExel has established itself as a leader in the clinical research field, serving the life sciences industry by supporting the discovery and development of vital therapies. The organization boasts an extensive network that operates in several major metropolitan areas, providing unparalleled support in the design and execution of complex clinical trials.

The company leverages the expertise of world-class Principal Investigators and advanced patient engagement strategies to ensure the success of its studies. CenExel’s dedication to quality and the patient experience has led to the completion of thousands of studies with remarkable precision and efficiency.

Ultimately, CenExel’s commitment to enhancing leadership through strategic appointments, such as the addition of Sensenig, reflects its ongoing mission to improve patient outcomes and foster innovation in clinical development.

To learn more about CenExel and its contributions to the clinical research industry, visit www.cenexelresearch.com.